Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + carboplatin + liposomal doxorubicin
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral (niraparib), Intravenous (carboplatin), Intravenous (liposomal Doxorubicin)
01
Overview
A combination regimen of **niraparib** (a PARP inhibitor), **carboplatin** (a platinum-based chemotherapeutic agent), and **liposomal doxorubicin** (an anthracycline cytotoxic drug formulated for improved tolerability and efficacy), primarily investigated as therapy for platinum-sensitive and recurrent ovarian cancer. Niraparib inhibits poly(ADP-ribose) polymerases involved in DNA repair, enhancing tumor cell death, especially in homologous recombination-deficient tumors. Carboplatin induces DNA cross-linking and apoptosis. Liposomal doxorubicin intercalates DNA and inhibits topoisomerase II, blocking DNA replication in rapidly dividing cells. The combination is explored for potential synergistic cytotoxic and DNA repair–inhibitory effects in ovarian cancer[3][5].
02
Targets
DNAPARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)Pol II (RNA polymerase II elongation factors)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on niraparib + carboplatin + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + carboplatin + liposomal doxorubicin.